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Oxidative damages in tubular epithelial cells in
IgA nephropathy: role of crosstalk between
angiotensin II and aldosterone
Joseph CK Leung*, Loretta YY Chan, Sydney CW Tang, Man-Fai Lam, Chui-Wa Chow, Ai-Ing Lim and Kar-Neng Lai
Abstract
Background: Inhibition of the renin-angiotensin-aldosterone system (RAAS) slows down the progression of chronic
renal diseases (CKD) including IgA nephropathy (IgAN). Herein, we studied the pathogenetic roles of aldosterone
(Aldo) in IgAN.
Methods: Human mesangial cells (HMC) was activated with polymeric IgA (pIgA) from IgAN patients and the
effects on the expression of RAAS components and TGF-b synthesis examined. To study the roles of RAAS in the
glomerulotubular communication, proximal tubular epithelial cells (PTEC) was cultured with conditioned medium
from pIgA-activated HMC with eplerenone or PD123319, the associated apoptotic event was measured by the
generation of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase and reactive oxygen species (ROS).
Results: Polymeric IgA up-regulated the Aldo synthesis and aldosterone synthase expression by HMC. The release
of TGF-b by HMC was up-regulated synergistically by AngII and Aldo and this was inhibited by incubation of HMC
with losartan plus eplerenone. Cultured PTEC express the mineralocorticoid receptor, but not synthesizing
aldosterone. Apoptosis, demonstrated by cleaved PARP expression and caspase 3 activity, was induced in PTEC
activated by conditioned medium prepared from HMC cultured with pIgA from IgAN patients. This apoptotic event
was associated with increased generation of NADPH oxidase and ROS. Pre-incubation of PTEC with PD123319 and
eplerenone achieved complete inhibition of PTEC apoptosis.
Conclusions: Our data suggest that AngII and Aldo, released by pIgA activated HMC, served as mediators for
inducing apoptosis of PTEC in glomerulo-tubular communications. Crosstalk between AngII and Aldo could
participate in determining the tubular pathology of IgAN.
Background
IgA nephropathy, the most common primary glomerulo-
nephritis worldwide, is associated with a substantial risk
of progression to end-stage renal failure (ESRF) [1]. The
disease runs a highly variable clinical course. A sub-
group of IgAN with tubulointerstitial damage is often
associated with the most rapid progression to ESRF [2].
We have previously documented that mesangial IgA
deposition induces local release of pro-inflammatory
cytokines leading to glomerular inflammation [3,4]. The
renin-angiotensin system (RAS) is strongly involved in
the development of progressive renal fibrosis with local
AngII hyperactivity occurring in IgAN [5-7]. We had
revealed that IgA from IgAN patients was capable of
up-regulating the TGF-b production via increased AngII
release by HMC following binding to pIgA [8]. We
further demonstrated altered expression of mesangial
and tubular angiotensin receptors in response to raised
intra-renal AngII in IgAN [3,4,9]. Although these data
shed light on the importance of AngII and RAS in the
pathogenesis of IgAN, a possible link between the aldos-
terone system and IgAN remains lacking. Aldosterone is
an important mediator bearing injurious actions of the
RAAS in chronic heart failure and renal disease [10-13].
Aldo promotes fibrosis and vascular toxicity in experi-
mental animal models [14-16]. The specific action of
Aldo is mediated through the mineralocorticoid receptor
(MR) in the presence of 11ß-hydroxysteroid
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dehydrogenase type II (11ß-HSD2) [13]. In humans,
exogenous aldosterone increases circulating interleukin-
6 (IL-6) concentrations and MR antagonism attenuates
AngII-induced IL-6 increase [17], suggesting that endo-
genous aldosterone may contribute to the pro-inflam-
matory effects of AngII. AngII inhibition combined with
Aldo blockade effectively reduces proteinuria in human
CKD [18]. All these evidences suggest that Aldo may
also be involved in the pathophysiology of IgAN.
Methods
Materials
Reagents used for cell culture were obtained from Life
Technologies (Rockville, MD, USA). Monoclonal anti-
MR was obtained from Abcam (Cambridge, MA, USA).
Rabbit anti-11ß-HSD2 was obtained from Cayman Che-
mical (Ann Arbor, MI, USA). Goat anti-CYP11B2, rabbit
polyclonal anti-AT1R (AT1R) and AngII receptor sub-
type-II (AT2R) were from Santa Cruz Biotechnology
(Santa Cruz, CA, USA). Monoclonal anti-cleaved poly-
(ADP-ribose)-polymerase (PARP) was obtained from
Cell Signaling Technology (Beverly, CA, USA). Mono-
clonal anti-actin was obtained from Neomarkers (Fre-
mont, CA, USA). F(ab’)2 fragment of Alexa Fluor 488-
conjugated goat anti-mouse, donkey anti-goat, goat anti-
rabbit immunoglobulin G (IgG) antibodies were
obtained from Invitrogen Ltd. (Paisley, UK). The Envi-
sion Plus System was obtained from Dako (Carpinteria,
CA, USA). Peroxidase labeled anti-goat antibody was
obtained from Jackson ImmunoResearch Laboratories,
Inc. (West Grove, PA, USA). 4’,6’-diamidino-2-phenylin-
dole hydrochloride (DAPI) was obtained from Molecular
Probe (Eugene, OR, USA). Human total kidney RNA
was obtained from Life Technologies Corporation
(Carlsbad, CA, USA). Angiotensin II, aldosterone, angio-
tensin-converting enzyme inhibitor (ACEI), eplerenone,
AngII receptor antagonist and other chemicals were
obtained from Sigma (St. Louis, MO, USA).
Study Population
The study protocol was approved by the Research Ethics
Committee of the University of Hong Kong and was
carried out in accordance with the principles of Declara-
tion of Helsinki. Twenty-seven Chinese patients (12
male and 15 female) with clinical and renal immuno-
pathological diagnosis of primary IgAN were studied.
Fifty milliliters of blood were collected from each stu-
died subject at clinical quiescence (no macroscopic
hematuria with urinary erythrocyte count < 10,000/ml
in un-centrifuged urine). The serum was isolated and
frozen at -20°C until for isolation of pIgA1. Twenty-two
healthy subjects (10 male and 12 female), comparable in
age and race, with no microscopic hematuria or protei-
nuria, were recruited as controls.
Purification of pIgA
Jacalin binding protein (JBP) was purified using a jaca-
lin-agarose affinity column and pIgA was fractionated
by the FPLC as described previously [19].
Cell Culture and Preparation of Conditioned Medium
Isolation and characterization of HMC and PTEC were
performed as previously described [4,20]. Growth
arrested HMC were cultured in six-well culture plates (1
× 106 cells per well) with culture medium containing
0.5% FBS and pIgA (final concentration 0.5 mg/ml) iso-
lated from patients with IgAN or controls for 48 hours.
The conditioned medium (IgA-HMC medium) after cul-
ture were collected and kept frozen at -70°C until used.
Conditioned medium from HMC cultured without the
addition of IgA preparation was used as plain medium
control.
Expression of MR, 11b-HSD2 or CYP11B2 in HMC and
PTEC
HMC or PTEC were cultured with pIgA (0.5 mg/ml)
from controls or IgAN patients, or IgA-HMC medium
from IgAN patients (for PTEC only), for 6 h (for RNA
expression) or 24 h (for protein determination). The
expression of MR, 11b-HSD2 and CYP11B2 were deter-
mined by qPCR and immunoblotting. Expression of
CYP11B2 in HMC or MR in PTEC was also examined
using immunofluorescence staining.
Cell Culture Experiments
To determine the dose- or time-course of CYP11B2
expression or Aldo synthesis by HMC, growth arrested
HMC were cultured with pIgA (0.125 to 2 mg/ml) or
AngII (10-12 to 10-8 M) for 6 h (for RNA expression) or
48 h (for protein or Aldo assay); or with pIgA (0.5 mg/
ml) or AngII (10-10 M) for 6 h to 96 h. To determine
the dose course of angiotensinogen and ACE expression
or AngII release by HMC, growth arrested HMC were
cultured with Aldo (10-12 to 10-8 M) for 6 h (total RNA
purification) or 48 h (for AngII assay). To examine
whether there was synergistic effect of AngII and Aldo
on TGF-b synthesis by HMC, growth arrested HMC
were cultured with different concentrations of Aldo,
AngII or their combination (10-12 to 10-8 M) for 48 h.
For studying the role of MR and AT1R in pIgA induced
TGF-b synthesis by HMC, HMC were pre-incubated
with losartan (100 mM) or/and eplerenone (10 μM) one
hour before addition of pIgA.
To examine the differential effect of pIgA, conditioned
medium, AngII and Aldo on expression of MR or
AT2R, ROS generation and NADPH oxidase activity by
PTEC, growth arrested PTEC were cultured with (i)
pIgA (0.5 mg/ml) from IgAN patients; (ii) 4 fold diluted
IgA-HMC medium prepared from controls or IgAN
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patients; (iii) Aldo (10-10 M) or (iv) AngII (10-10 M) for
6 h (for mRNA) or 48 h (for protein). PTEC were also
pre-incubated with losartan (100 mM), PD123319 (10
μM), eplerenone (10 μM) or their combinations one
hour before experiments for studying the role contribu-
ted by MR, AT1R or AT2R in ROS generation and cas-
pase 3 activity induced by conditioned medium or
AngII.
To determine the time-course of cleaved PARP or cas-
pase 3 activity in PTEC, PTEC were cultured with (i)
pIgA (0.5 mg/ml) from IgAN patients; (ii) 4 fold diluted
IgA-HMC medium prepared from controls or IgAN
patients; (iii) Aldo (10-10 M) or (iv) AngII (10-10 M) for
different time points For dose-course study, PTEC were
cultured with various concentrations or dilutions of (i)
pIgA from IgAN patients; (ii) IgA-HMC from controls
or IgAN patients; (iii) Aldo or (iv) AngII for 48 h.
Immunohistochemistry Examination
Renal tissues were obtained from eight normotensive
patients with mild IgAN (grade 1) consecutively
admitted for diagnostic renal biopsy with the presenta-
tion of microscopic haematuria. They had not previously
received angiotensin-converting enzyme inhibitor or
Ang II receptor subtype-1 (ATR1) antagonist. Control
renal tissues were obtained from the intact pole of kid-
neys removed for single circumscribed tumor in seven
normotensive subjects (comparable in age, sex and
race). Glomerular and tubular expression of MR, 11b-
HSD2 and CYP11B2 were detected by immunoperoxi-
dase staining using specific antibodies. The bound
monoclonal anti-MR or rabbit polyclonal anti-11b-
HSD2 antibodies were visualized in brown using the
Dako Envision Plus System. The bound goat anti-
CYP11B2 antibodies were detected with peroxidase
labeled anti-goat antibodies and visualized in brown
using 3,3’-diaminodbenzidine (DAB). Negative controls
were done with primary antibodies absorbed with rele-
vant antigens before the first incubation. Two renal
pathologists without prior knowledge of clinical or
laboratory data evaluated the expression of MR, 11b-
HSD2 and CYP11B2 using an arbitrary 0-5+ scale [4,9].
Immunoblotting
HMC or PTEC were harvested and dissolved in protein
extraction buffer containing protease inhibitor cocktails.
Total protein from HMC (50 μg) or PTEC (10 μg) was
electrophoresed through a 15% SDS-PAGE and then
transferred to the polyvinylidene fluoride (PVDF) mem-
brane. The membrane was incubated overnight with
anti-CYP11B2 (1:1000), anti-AT2R (1:1000), anti-MR
(1:1000) or anti-actin (1:1000) antibody in PBS-Tween
before reacting with appropriate peroxidase-labeled sec-
ondary antibodies (Dako, Kyoto, Japan). The reaction
was detected with ECL plus chemiluminescent detection
reagent (Amersham Pharmacia Biotech, Uppsala, Swe-
den). The images were scanned and the density of the
bands was quantitated using the ImageQuant software
(Molecular Dynamic, Sunnyvale, CA, USA). The densi-
tometric results were reported as average arbitrary inte-
grated values (units) after normalization with the
average arbitrary integrated values of the actin signal.
Detection of Cleaved PARP Expression in HMC and PTEC
Cell extracts were prepared from HMC or PTEC. Early
apoptosis was detected by immunoblotting using mono-
clonal anti-PARP antibody (1:500) that recognized the
89 kDa cleaved PARP fragment. The membrane was
then washed and incubated for 2 hours at room tem-
perature with a peroxidase-labeled goat anti-mouse
immunoglobulin (Dako, Kyoto, Japan). The reaction was
quantitated as described in the previous section.
Real-time RT-PCR
Real-time RT-PCR was performed as previously
described [21]. Primer sequences and gene bank acces-
sion numbers are listed in Table 1. Data obtained were
analyzed using the comparative CT (cycle threshold)
method.
Determination of TGF-b, AngII or Aldo in Supernatant
from Cultured HMC
TGF-b in supernatant from HMC culture was deter-
mined with the ELISA kits from R&D Systems (Minnea-
polis, MN, USA). The detection sensitivity was 32 pg/ml
Table 1 Primer sequences for qPCR
Gene Forward primer sequences Reward primer sequences
CYP11B2 5’-TACAGGTTTTCCTCTACTCG 5’-AGATGCAAGACTAGTTAATC
11b-HSD2 5’-GGCCACAATGAAGTAGTTGC 5’-CTCCCCACAGTCACGATG
ANG 5’-CTGCAAGGATCTTATGACCTGC 5’-TACACAGCAAACAGGAATGGGC
ACE 5’-CCGAAATACGTGGAACTCATCAA 5’-CACGCGTCCCCTGCATCTACA
MR 5’-TCTGACTCTGGGAGCTCCGT 5’-TCCTCCTAGACATGAGCTGC
AT2R 5’-AGTAAGCACAGAATTCAAAG 5’-AGTAAAGAATAGGAATTGCAT
GAPDH 5’-CTCTCTGCTCCTCCTGTTCGAC 5’-TGAGCGATGTGGCTCGGCT
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and the inter-batch coefficients of variation was 6.5%.
AngII and Aldo were measured by an enzyme immu-
noassay kit (Cayman) according to the manufacturer’s
instruction. The minimum detectable concentration for
AngII and Aldo was 1 and 7.8 pg/ml respectively with
corresponding intra-assay coefficient of variation of 7
and 12.5%.
Quantification of Apoptosis, Determination of ROS and
NADPH Oxidase Activity
Activation of caspase 3 in PTEC cultured with IgA-
HMC conditioned medium was determined using the
caspase 3 activity fluorometric immunosorbant enzyme
assay kit (Roche Diagnostics) according to manufac-
turer’s protocol. ROS generation was measured with the
fluoroprobe carboxymethyl-H2-dichlorofluorescein dia-
cetate. Nicotinamide adenine dinucleotide phosphate
(NADPH) oxidase activity was determined using an
assay based on the chemiluminescence of lucigenin (bis-
N-methylacridinium nitrate).
Statistics
All data were expressed as means ± standard deviation
(SD) unless otherwise specified. Statistical difference was
analyzed with multivariate ANOVA for repeated mea-
sures. All p-values quoted are two-tailed and the signifi-
cance is defined as p < 0.05.
Results
Expression of CYP11B2 and 11b-HSD2 in HMC and Their
Regulation by pIgA
Cultured HMC expressed mRNA for the CYP11B2 and
11b-HSD2 constitutively and pIgA from IgAN patients
up-regulated the gene (Figure 1A) and protein (Figure
1B) expression of CYP11B2 (p < 0.05), without altering
the mRNA expression of 11b-HSD2. Up-regulation of
CYP11B2 expression in HMC by pIgA from IgAN
patients was confirmed by immunofluorescence staining
(Figure 1C). A time- and dose-dependent increase in
CYP11B2 expression in HMC was only demonstrated
with pIgA from IgAN patients, but not with control
pIgA (Figure 2).
Aldo Up-regulated Mesangial Release of AngII
Polymeric IgA from IgAN patients but not with pIgA
from controls, at concentration > 0.25 mg/ml signifi-
cantly increased the release of Aldo by HMC in a dose
dependent manner (Figure 3A). At a concentration of
Figure 1 Increased expression of CYP11B2 in HMC cultured with pIgA. (A) There was increased expression of CYP11B2 mRNA and (B)
CYP11B2 protein, but not 11b-HSD2, by HMC cultured with pIgA from patients (IgAN, n = 27) as compared to that of the controls (Control, n =
22). The results represent the mean ± SD. (C) Increased expression of CYP11B2 (arrow) in HMC was confirmed by immunofluorescence staining
(magnification × 200).
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0.5 mg/ml, only pIgA from IgAN patients induced a
time-dependent increase of Aldo in cultured HMC (Fig-
ure 3B). Exogenous AngII increased the Aldo release
and CYP11B2 protein expression in a dose- and time-
dependent manner (Figures 3C and 3D). Aldo at con-
centration > 10-11 M increased the release of AngII and
gene expression of angiotensinogen and ACE by HMC
(Figure 4A).
Role of Aldo and AngII in Regulation of TGF-b Synthesis
by HMC
AngII and Aldo at concentration >10-11 M individually
increased TGF-b synthesis by HMC with synergistic
effect (Figure 4B). Pre-incubation of HMC with either
losartan or eplerenone partially reduced the pIgA-
induced TGF-b synthesis by HMC (Figure 4C). The
increased mesangial TGF-b synthesis induced by pIgA
was completely abolished with dual blockade of losartan
and eplerenone (Figure 4C).
Expression of MR, but not CYP11B2 or 11b-HSD2 by PTEC
Mineralocorticoid receptor mRNA was constitutively
expressed in PTEC, but not for mRNA of CYP11B2 or
11b-HSD2 (Figure 5A). There was no induction of
CYP11B2 or 11b-HSD2 gene expression in PTEC cul-
tured with pIgA or conditioned medium from HMC
incubated with pIgA from IgAN patients (IgA-HMC
medium) (data not shown). Immunofluorescence stain-
ing confirmed the expression of MR in the resting
PTEC (Figure 5B).
Expression of MR, CYP11B2 or 11b-HSD2 in Human IgAN
Data on the expression of MR, CYP11B2 or 11b-HSD2 in
cultured HMC or PTEC were further confirmed by immu-
nohistochemical staining in kidney biopsies from patients
with IgAN (Figure 5C). When compared with the staining
results of the control biopsies, there was significantly
increased expression of glomerular CYP11B2 and tubular
MR in patients with IgAN (Figures 5D and 5E).
Figure 2 Dose- and time-dependent CYP11B2 expression in HMC. (A) Significant up-regulation of CYP11B2 mRNA expression and (B)
CYP11B2 protein synthesis by HMC exposed to pIgA from IgAN patients (IgAN), but not with pIgA from controls (Control). (C) HMC cultured
with pIgA (0.5 mg/ml) from IgAN, but not with pIgA from controls, exhibited an time-dependent increase of CYP11B2 mRNA expression (from 6
h, peaked at 12 h) and (D) CYP11B2 protein synthesis (from 24 h peaked at 48 h). The results represent the mean ± SD from five individual
experiments. * signifies p < 0.05 when compared with data from HMC cultured in plain medium or data from time zero.
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Regulation of MR and AT2R expression in PTEC
Both exogenous AngII and IgA-HMC medium prepared
from IgAN patients significantly increased the expres-
sion of MR and AT2R in PTEC (Figures 6A to 6D) as
compared with plain medium. The AT2R antagonist,
PD123319, effectively abolished the enhanced expression
of MR (Figure 7). In contrast, neither losartan nor epler-
enone exhibited any inhibitory action.
AngII, Aldo or IgA-HMC Medium from IgAN Patients
Induced Apoptosis in PTEC
PTEC cultured with Aldo (10-10 M), AngII (10-10 M) or
4-fold diluted IgA-HMC medium prepared from IgAN
patients, induced cellular apoptosis as indicated by time-
and dose-related up-regulation of cleaved PARP expres-
sion (Figures 8A and 8B) and caspase 3 activity (Figures
9A and 9B). Similar findings were not observed with
conditioned medium prepared from controls or direct
culture with pIgA from IgAN patients. The induced
apoptosis in PTEC was associated with increased reac-
tive oxygen species (ROS) generation and NAPDH oxi-
dase activity (Figures 10A and 10B). The ROS
generation and caspase 3 activity induced by Aldo,
AngII or IgA-HMC medium prepared from IgAN
patients were partially suppressed by PD123319 or
eplerenone and completely abolished with combined use
of PD123319 and eplerenone (Figure 11). AT1R block-
ade with losartan exhibited no suppressive effect.
Discussion
In this study, in vitro culture models of HMC and PTEC
were used to examine Aldo synthesis by pIgA directly or
through glomerular-tubular communications. The possi-
ble role of Aldo on PTEC injury and its interaction with
AngII in IgAN was also elucidated. The RAS has been
implicated in the development of progressive
Figure 3 Dose- and time-dependent Aldo release and CYP11B2 expression in HMC. (A) Significant increase in Aldo release by HMC
exposed to increasing concentration of pIgA from IgAN patients. (B) HMC cultured with pIgA (0.5 mg/ml) from IgAN patients, exhibited time-
related increase in Aldo release (from 12 h, peaked at 48 h). (C) AngII induced Aldo release (at concentration > 10-12 M) and CYP11B2 protein
synthesis (at concentration > 10-11 M) from HMC. (D) AngII (10-10 M) induced time-related increase of Aldo release and CYP11B2 protein
synthesis in HMC. The results represent the mean ± SD from five individual experiments. * signifies p < 0.05 when compared with data from
HMC cultured in plain medium or data from time zero.
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glomerulosclerosis in diabetic and non-diabetic nephro-
pathy [22,23]. We had previously demonstrated an
increased expression of renin and TGF-b by HMC incu-
bated with pIgA from IgAN patients [8]. Polymeric IgA
from these patients also up-regulated the Smad activity
in HMC which was readily suppressed with captopril or
losartan, supporting a pathogenetic role of pIgA1 in
IgAN through up-regulation of the RAS and TGF-b.
Growing evidence from experimental and clinical studies
indicates that increased Aldo is an independent contri-
butor to arterial injury and nephropathy [24]. Both
human and rat mesangial cells produce Aldo in culture
[25,26]. Exogenous Aldo significantly increased fibronec-
tin production by mesangial cells [26]. Renal TGF-ß and
fibronectin are increased in Dahl salt-sensitive rat with
heart failure (DSHF rat) in association with the develop-
ment of glomerulosclerosis [27]. Aldo blocker signifi-
cantly suppressed renal TGF-ß expression in DSHF rat
with reduced glomerulosclerosis. In vivo study also
showed Aldo administration per se induced TGF-ß
release and organ fibrosis independent of blood pressure
[28]. In the present study, we demonstrate that Aldo
may initiate and amplify injury to HMC upon activation
by pIgA in both paracrine and endocrine manner. We
also reveal a vicious cycle between pIgA-induced AngII
and Aldo amplifying the TGF-b synthesis via binding to
AT1R and MR in cultured HMC in the setting mimick-
ing IgAN.
Figure 4 Effect of Aldo or pIgA on TGF-b synthesis and RAS of HMC. (A) Aldo at concentration >10-11 M increased the mRNA expression of
angiotensinogen and ACE, and AngII release by HMC. (B) AngII or Aldo at concentration >10-11 M increased TGF-b synthesis by HMC. AngII and
Aldo showed synergistic effect on TGF-b synthesis by HMC. * signifies p < 0.05 when compared with data from control without Aldo or AngII.
(C) Pre-incubation with losartan (100 mM) or eplerenone (10 μM) one hour before cultured with pIgA from IgAN patients partially reduced the
pIgA-induced TGF-b synthesis by HMC. Combining losartan and eplerenone completely abolished the increased TGF-b synthesis by pIgA. The
AngII effect on TGF-b synthesis was blocked by losartan and the Aldo effect blocked by eplerenone; with complete normalization of TGF-b
synthesis with the presence of both blockers. ** and * signify p < 0.01 and p < 0.05 respectively when compared with data from HMC cultured
with pIgA from controls (Control). ## and # signify p < 0.01 and p < 0.05 respectively when compared with data from HMC pre-incubated with
both inhibitors. The results represent the mean ± SD from five individual experiments.
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Using similar in vitro culture model, we had pre-
viously demonstrated that that tumor necrosis factor-a
(TNF-a) and AngII are released from mesangial cells
following initial deposition of “pathogenetic” pIgA [3].
This is followed by mesangial proliferation and glomeru-
lar infiltration of immuno-competent cells. A cross-talk
network initiated by TNF-a, AngII and other soluble
factors orchestrates interactions between infiltrating
immuno-competent cells and the resident renal cells,
forming a major driving force of tubulointerstitial injury.
We further demonstrate that AngII, but not Aldo,
released by pIgA-activated HMC up-regulate the expres-
sion of AT2R and MR by PTEC. The increased MR
expression in PTEC is readily available for the binding
to Aldo, released by the pIgA-activated HMC, to initiate
the downstream events of PTEC injury. Our observation
of an up-regulation of MR but not 11b-HSD2 in PTEC
is intriguing. Previously, it is believed that the specificity
for MR to Aldo is conferred enzymatically by the corti-
sol-inactivating enzyme 11b-HSD2 [29,30]. However,
recent evidence has suggested that it may not be totally
true as it is improbable for the intrarenal 11b-HSD2 to
convert all the glucocorticoid molecules to MR-inactive
metabolites with the inexhaustible supply of steroid sub-
strate [31]. The current view suggests that the enzyme
11b-HSD2 does not block the glucocorticoid occupancy
of MR but the ability of glucocorticoid to act as
MR agonist. In the absence of the enzyme, there is
intracellular redox change due to reduced generation of
nicotinamide-adenine dinucleotide (NADH) from
Figure 5 Expression of MR, 11b-HSD2 or CYP11B2 in cultured HMC, PTEC and kidney biopsies. (A) HMC expressed MR, 11b-HSD2 and
CYP11B2 mRNAs and PTEC expressed only MR mRNA. Result was expressed as the mean fold change ± SD (related to the mean CT value from
positive control using purified kidney total mRNA) from five individual experiments. (B) Demonstration of MR expression (arrows) in cultured
PTEC by immunofluorescence staining (magnification × 200). (C). Detection of MR, 11b-HSD2 and CYP11B2 in kidney biopsies from IgAN patients
and controls. Immunoreactive MR was located in both the glomeruli and tubules. Signal from immunoreactive 11b-HSD2 and CYP11B2 was
located in glomeruli but not tubules (magnification × 200). Compared to staining results in control biopsies, increased (D) glomerular CYP11B2
staining and (E) tubular MR staining in IgAN patients were semi-quantified using a five-point scale.
Leung et al. Journal of Translational Medicine 2011, 9:169
http://www.translational-medicine.com/content/9/1/169
Page 8 of 15
Figure 6 Effect of pIgA, IgA-HMC conditioned medium, AngII and Aldo on the expression of MR or AT2R. Growth arrested PTEC was
cultured with (i) pIgA (IgA, 0.5 mg/ml) from IgAN patients; (ii) 4 fold diluted IgA-HMC medium prepared from controls or IgAN patients; (iii) Aldo
(10-10 M) or (iv) AngII (10-10 M). Both the exogenous AngII and IgA-HMC medium prepared from IgAN patients significantly increased the
expression of (A) MR mRNA, (B) MR protein, (C) AT2R mRNA and (D) AT2R protein as compared with PTEC cultured with plain medium control
(** signifies p < 0.01). The results represent the mean ± SD from five individual experiments.
Figure 7 The effect of MR, AT1R or AT2R blockade on IgA-HMC medium or AngII induced MR or AT2R expression. PD123319 effectively
abolished the up-regulation of MR and AT2R receptor mRNA (A) or protein expression (B & C) by IgA-HMC medium from IgAN patients (medium-
IgA) or AngII. Neither losartan nor eplerenone altered these receptors expression in PTEC. * and ** signify p < 0.05 and p < 0.01 respectively when
compared with data from PTEC cultured in plain medium. The results represent the mean ± SD from five individual experiments.
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nicotinamide-adenine dinucleotide (NAD), the co-sub-
strate for the cortisol-to-cortisone conversion [31,32]. It
has been demonstrated by patch-clamp study in isolated
rabbit cardiomyocytes that under normal conditions,
cortisol is an MR antagonist on the Aldo-induced trans-
membrane pump current. However, cortisol becomes an
MR agonist, mimicking the effect of aldosterone, under
redox change with instillation of oxidized glutathione
[33]. It has been suggested that MR, which are constitu-
tively occupied by normal glucocorticoid levels,
responds to changes in intracellular redox state in tis-
sues either expressing (e.g. vascular smooth muscle
cells) [34] or lacking 11b-HSD2 (e.g. cardiomyocytes)
[35]. We speculate that apart from the increased
availability of MR expression to the up-regulated aldos-
terone release by pIgA-activated HMC in PTEC, cellular
cortisol in PTEC may also act agonistically on the up-
regulated MR in the absence of 11b-HSD2 under redox
changes. The combined effect of aldosterone and corti-
sol via MR may eventually lead to cellular apoptosis.
Our data reveal that PTEC cultured with AngII, Aldo or
IgA-HMC medium prepared from IgAN patients express
increased NADPH oxidase and ROS formation. The
events are associated with increased apoptosis in PTEC
demonstrated by dose- and time-dependent up-regulation
of cleaved PARP expression and caspase 3 activity. The
primary function NADPH oxidase is to generate ROS
[36,37]. Although the NADPH oxidase was originally
Figure 8 Time- and dose-related expression of cleaved PARP by PTEC. (A) Up-regulation of cleaved PARP expression by PTEC cultured with
Aldo (10-10 M), AngII (10-10 M) or 4 fold diluted IgA-HMC medium prepared from IgAN patients (medium-IgAN). Similar up-regulation was not
observed with IgA-HMC medium from controls (medium-Ctl) or pIgA alone (IgA). (B) Dose-dependent up-regulation of cleaved PARP expression by
PTEC cultured with Aldo, AngII or IgA-HMC medium prepared from IgAN patients. * and ** signify p < 0.05 and p < 0.01 respectively when
compared with data from time zero or from PTEC cultured in plain medium. The results represent the mean ± SD from five individual experiments.
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identified in phagocytic leukocytes, recent study discov-
ered that this enzyme is an essential endogenous origin of
cellular oxidative stress and cellular injury in other cell
types [36]. Furthermore, ROS generated by the NADPH
oxidase may also modulate many intracellular redox signal
transduction pathways [36]. PTEC process all components
of the NADPH oxidase complex [36,38,39]. The exact
function of NADPH oxidase in regulating physiological
and pathophysiological processes in the kidney remains
unknown. Data from in vitro experiments have shown that
NADPH oxidase-derived ROS mediate apoptosis in renal
cells [39,40]. AngII is an important in vivo regulator of
NADPH oxidase in the kidney through activation of renal
NADPH oxidase and induction of oxidative stress [38].
Recent data from transgenic mouse model suggest that
up-regulation of NADPH oxidase-dependent ROS genera-
tion is important in mediating apoptosis in renal tubular
epithelial cell induced by AngII. Apart from AngII, our
present study provides novel in vitro data showing that
Aldo also induces NADPH oxidase expression and its
dependent ROS generation by PTEC. Further in vivo
experiment is needed to validate the role of Aldo in indu-
cing PTEC apoptosis through NADPH oxidase and ROS
generation.
Blockade of the RAS with ACEI or AT1R blocker
protects hypertensive and diabetic kidney injuries by
inhibiting the renal NADPH [41-43]. Aldo also
enhances NADPH oxidase activity via translocation of
Figure 9 Time- and dose-related assay of caspase 3 activity in PTEC. (A) Up-regulation of caspase 3 activity by PTEC cultured with Aldo (10-
10 M), AngII (10-10 M) or 4 fold diluted IgA-HMC medium prepared from IgAN patients (medium-IgAN); Similar up-regulation was not observed
with IgA-HMC medium from controls (medium-Ctl) or pIgA alone (IgA). (B) Dose-dependent up-regulation of caspase 3 activity by PTEC cultured
with Aldo, AngII or IgA-HMC medium prepared from IgAN patients. * and ** signify p < 0.05 and p < 0.01 respectively when compared with
data from time zero or from PTEC cultured in plain medium. The results represent the mean ± SD from five individual experiments.
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the cytosolic component, p47phox, to the membrane
subunits by an ERK1/2-related pathway [44]. Aldo has
also been shown to stimulate angiotensin-converting
enzyme (ACE) expression which stimulates renal AngII
production [45]. Recent clinical studies indicate that
Aldo blockade may provide renoprotection by decreas-
ing proteinuria, independent of blood pressure control.
The combination of ACEI and the selective Aldo
blocker, eplerenone, can provide a better renal out-
come with reduction of proteinuria and kidney damage
Figure 10 ROS generation and NADPH oxidase activity by PTEC. (A) Up-regulation of ROS generation and (B) NADPH oxidase activity by
PTEC cultured with Aldo (10-10 M), AngII (10-10 M) or 4 fold diluted IgA-HMC medium prepared from IgAN patients (IgAN); Similar up-regulation
was not observed with IgA-HMC medium from controls (Ctl) or pIgA alone (IgA). ** signify p < 0.01 when compared with data from PTEC
cultured in plain medium. The results represent the mean ± SD from five individual experiments.
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than monotherapy [24,46]. Interestingly, treatment
with eplerenone alone or combining with the ACEI
reduced proteinuria more effectively than the ACEI
alone in human studies [47,48]. In DSHF rat, com-
bined therapy with eplerenone and ACEI reduced glo-
merulosclerosis, proteinuria and improved renal
function more effectively than monotherapy [27].
Based on the finding of up-regulated expression of MR
and AT2R in PTEC by IgA-HMC medium from IgAN
patients and AngII, we tested whether combined
blockade of AT2R and MR could suppress pIgA-
induced PTEC apoptosis through the glomerulo-
tubular communication. Our present data confirm that
blockade with PD123319 and eplererone abolishes
NADPH-dependent ROS generation and apoptosis.
Further in vivo study is needed to test whether com-
bined AngII receptor and Aldo blockade provides a
better renal outcome with reduction of proteinuria and
tissue damage in IgAN.
Based on our previous studies [3,4,8,9,49] and the pre-
sent data, a mechanistic schema summarizing the con-
tributory role of the RAAS in glomerulo-tubular
communications operating in tubulointerstitial injury in
IgAN is shown in Figure 12.
Figure 11 The effect of MR, AT1R or AT2R blockade in ROS generation and caspase 3 activity by PTEC. (A) Individual use of MR, AT1R or
AT2R antagonist failed to effectively inhibit the up-regulation of ROS generation and (B) caspase 3 activity by PTEC cultured with Aldo (10-10 M),
AngII (10-10 M) or 4 fold diluted IgA-HMC medium prepared from IgAN patients (medium-IgAN). Abolishment of up-regulated ROS generation
and caspase 3 activity by PTEC was only achieved by combining PD123319 and eplerenone. * and ** signify p < 0.05 and p < 0.01 respectively
when compared with data from HMC cultured with plain medium control. ## and # signify p < 0.01 and p < 0.05 respectively when compared
with data from HMC corresponding activator without pre-incubation of any receptor antagonist. The results represent the mean ± SD from five
individual experiments.
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Conclusions
Taken together, our in vitro data suggest that AngII
and Aldo, released by pIgA1 activated HMC, are med-
iators for glomerulotubular crosstalk in inducing apop-
tosis of PTEC through NADPH dependent generation
of ROS. In addition, crosstalk between AngII and Aldo
could play a role in pIgA1 induced PTEC apoptosis in
IgAN.
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